Bayer, Elanco could lock up animal health merger next week: report

When rumors emerged nearly a year ago that Bayer might be planning to exit the animal health business, private equity players topped most market watchers' lists of potential buyers. Now Eli Lilly spinoff Elanco tops that list—and the deal could be wrapped up soon.